Tasly Reports 9M Net Profit of RMB1.103B, Up 12.01% YoY

The divergence between falling revenue and rising profit is the story here: Tasly is earning more from a smaller top line, and the much faster growth in non-recurring net profit suggests cost discipline and mix, rather than volume, are doing the work. That matters for anyone tracking whether traditional Chinese medicine names can defend margins in a shrinking revenue environment. The third quarter is the caution flag — profit growth nearly stalled there even as non-recurring profit stayed strong, so whether the headline gains hold through the rest of the year is the open question.